Monalizumab
| Catalog Number | Pack Size | List Price* | Quantity | |
|---|---|---|---|---|
| HY-P99032-1MG | 1 mg | 402,00 | Add | |
| HY-P99032-5MG | 5 mg | 1'273,00 | Add | |
| HY-P99032-10MG | 10 mg | 2'022,00 | Add | |
| HY-P99032-25MG | 25 mg | 3'830,00 | Add |
* CHF, excl. 8.1% VAT and shipping costs
Product Description
Best price guarantee – we offer you the lowest price in Switzerland. Please contact us for a quote if needed.
IPH2201
Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A) . Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC) [1][2].
| Category | Antibody |
| Supplier | MedChem Express |
| Regulatory Status | RUO |
| Research Field | Cancer; Inflammation/Immunology |
| Format | Solubility: H2O |
| Grade | Clinical information: Phase 3 |
| Purity | 99.93% |
| CAS-Number | 1228763-95-8 |
| Storage Conditions | Store at -80°C for 2 years |
| Disclaimer | Shipped on dry ice - extra freight charge will occur |
| Product Line | Biosimilar |
| Tech. Data Sheet | View datasheet |
| Link To Supplier | http://www.medchemexpress.com |
| Shipping Details | Dry Ice |
| Material Safety Data Sheet | Download PDF |
